Evolution of Systemic Therapy in Metastatic Pancreatic Ductal Adenocarcinoma

Mandana Kamgar; Sakti Chakrabarti; Aditya Shreenivas; Ben George

doi:10.1016/j.soc.2021.06.004

Evolution of Systemic Therapy in Metastatic Pancreatic Ductal Adenocarcinoma

Surg Oncol Clin N Am. 2021 Oct;30(4):673-691. doi: 10.1016/j.soc.2021.06.004. Epub 2021 Jul 22.

Authors

Mandana Kamgar¹, Sakti Chakrabarti², Aditya Shreenivas², Ben George²

Affiliations

¹ Division of Hematology and Oncology, Department of Medicine, LaBahn Pancreatic Cancer Program, Medical College of Wisconsin, 9200 West Wisconsin Avenue, Milwaukee, WI 53226, USA. Electronic address: [email protected].
² Division of Hematology and Oncology, Department of Medicine, LaBahn Pancreatic Cancer Program, Medical College of Wisconsin, 9200 West Wisconsin Avenue, Milwaukee, WI 53226, USA.

PMID: 34511189
DOI: 10.1016/j.soc.2021.06.004

Abstract

Pancreatic ductal adenocarcinoma is characterized by early systemic dissemination, a complex tumor microenvironment, as well as significant intratumoral and intertumoral heterogeneity. Treatment options and survival in pancreatic ductal adenocarcinoma have improved steadily over the last 3 decades. Although cytotoxic chemotherapy is currently the mainstay of treatment for pancreatic ductal adenocarcinoma, evolving therapeutic strategies are aimed at targeting the tumor microenvironment, metabolism, and the tumor-host immune balance.

Keywords: Adenocarcinoma of the pancreas; Chemotherapy; Evolution; Pancreatic cancer; Systemic treatment.

Publication types

Review

MeSH terms

Adenocarcinoma*
Antineoplastic Combined Chemotherapy Protocols
Carcinoma, Pancreatic Ductal* / drug therapy
Humans
Pancreatic Neoplasms* / drug therapy
Tumor Microenvironment